Sign In
Buy OVID
$2.44
-0.0100 (-0.408%)
At Close: Jul 17, 2026
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04:10pm, Thursday, 12'th Nov 2020
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
12:26pm, Wednesday, 30'th Sep 2020
Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q...
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
12:00pm, Wednesday, 30'th Sep 2020
NEW YORK, Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension...
Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data
02:18pm, Friday, 28'th Aug 2020
Ovid Therapeutics has had an excellent year. The stock fell after announcing a $50mn offering on positive phase 2 data.
Altimmune COVID Update, And Other News: The Good, Bad And Ugly Of Biopharma
02:31am, Thursday, 27'th Aug 2020
Altimmune provides positive updates for AdCOVID. Ovid reports positive Phase 2 ELEKTRA study data.
Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. announced positive topline results from the Phase 2 ELEKTRA study of soticlestat.
Stocks making the biggest moves in the premarket: Target, Lowe's, J&J, Momenta, Gilead & more
12:01pm, Wednesday, 19'th Aug 2020
The stocks making the biggest moves in premarket trading include Target, Lowe's, J&J, Momenta, Gilead, and more.
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
12:00pm, Monday, 10'th Aug 2020
* Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020 * Multiple data readouts for soticlestat expected in
Novavax和武田宣布在日本合作Novavax的COVID-19候选疫苗
12:00am, Monday, 10'th Aug 2020
(美国商业资讯)--开发用于严重传染病的下一代疫苗的后期生物技术公司Novavax, Inc. (Nasdaq: NVAX)与武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4
Biogen's Alzheimer's Drug And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BIIB)
08:02am, Sunday, 09'th Aug 2020
Biogen receives priority review for Alzheimer’s drug candidate. PTC Therapeutics receives FDA nod for Evrysdi.
Novavax Announces Deals to Sell Covid-19 Vaccine in India, Japan, and Low-Income Countries
03:58pm, Friday, 07'th Aug 2020
The agreements follow the release of positive results on the biotech’s vaccine.
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
12:00am, Friday, 07'th Aug 2020
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharm
BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana
12:00am, Thursday, 06'th Aug 2020
BioLife Plasma Services announces opening of first plasma collection center in Louisiana.
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
01:00pm, Wednesday, 05'th Aug 2020
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi
Ovid Therapeutics Is Quickly Approaching A Transformational Valuation Milestone (NASDAQ:OVID)
02:26am, Wednesday, 05'th Aug 2020
Top-line data from OVID's first Phase 3 (NEPTUNE) trial of OV101 for Angelman Syndrome is due Q42020. Recent OV101 Rare Pediatric Disease designation means FDA will likely fast-track OV101's NDA submi
